Deere & Co. (0R2P)
London Exchange · UK · prices in USD · close of 19 Oct 2026
Key indicators
| Last close | USD 628.96 |
|---|---|
| 52-week range | 429.14 – 719.86 |
| Return, 1 month / 3 months | −7.4% / +7.4% |
| Return, 1 year / 3 years | +42.8% / +72.5% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 40 |
| Volatility (1 year) | 32.7% |
| Worst drawdown (1 year) | -21.5% |
| Average daily value traded | 1.84M USD |
| Dividend yield | 1.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Deere & Company makes agricultural machinery, including tractors, combines and planting equipment sold under the John Deere name, along with construction, forestry and turf care equipment. Its customers are farmers, contractors, landowners and businesses that depend on heavy machinery for fieldwork, building and grounds maintenance. The company also offers financing and support services for equipment purchases. Deere is based in the United States and serves customers in many countries around the world.
The shares are listed on the London Exchange in UK under the code 0R2P, and the price on this page is in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Deere & Co. (0R2P) trades on the London Exchange in UK. It last closed at USD 628.96 on 19 October 2026.
Its price-based Market X-Ray is 68 out of 100 (a fair price profile), ranking 700 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 42.8% and over the last three months it rose 7.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 71 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 6.1% | ||
| From 52-week high | -10.9% | ||
| Momentum | 76 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 7.4% | ||
| 6-month return | 9.1% | ||
| 12-month return, skipping the last month | 54.2% | ||
| Stability (higher is calmer) | 62 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 32.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.5% | ||
| Liquidity | 59 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.84M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 66 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 1.0% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −0.2% |
|---|---|
| 1 month | −7.4% |
| 3 months | +7.4% |
| 6 months | +9.1% |
| 1 year | +42.8% |
| 3 years | +72.5% |
| 5 years | – |
Signals
| 50-day / 200-day average | 654.66 / 593.02 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 26.22 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 Sep 2026 | USD 1.6200 |
| 29 Jun 2026 | USD 1.6200 |
| 30 Mar 2026 | USD 1.6200 |
| 30 Dec 2025 | USD 1.6200 |
| 30 Sep 2025 | USD 1.6200 |
| 27 Jun 2025 | USD 1.6200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.